|
1.
|
Dobkin BH: Clinical practice.
Rehabilitation after stroke. N Engl J Med. 352:1677–1684. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Murray CJ and Lopez AD: Global mortality,
disability, and the contribution of risk factors: Global Burden of
Disease Study. Lancet. 349:1436–1442. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Lopez AD, Mathers CD, Ezzati M, Jamison DT
and Murray CJ: Global and regional burden of disease and risk
factors, 2001: systematic analysis of population health data.
Lancet. 367:1747–1757. 2006. View Article : Google Scholar
|
|
4.
|
Rothwell PM, Algra A and Amarenco P:
Medical treatment in acute and long-term secondary prevention after
transient ischaemic attack and ischaemic stroke. Lancet.
377:1681–1692. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Paciaroni M and Bogousslavsky J: Primary
and secondary prevention of ischemic stroke. Eur Neurol.
63:267–278. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Donnan GA, Fisher M, Macleod M and Davis
SM: Stroke. Lancet. 371:1612–1623. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
The Canadian Cooperative Study Group: A
randomized trial of aspirin and sulfinpyrazone in threatened
stroke. N Engl J Med. 299:53–59. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
The Dutch TIA Trial Study Group: A
comparison of two doses of aspirin (30 mg vs. 283 mg a day) in
patients after a transient ischemic attack or minor ischemic
stroke. N Engl J Med. 325:1261–1266. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Farrell UK-TIA Study Group: The United
Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final
results. J Neurol Neurosurg Psychiatry. 54:1044–1054. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Kral M, Herzig R, Sanak D, et al: Oral
antiplatelet therapy in stroke prevention. Minireview. Biomed Pap
Med Fac Univ Palacky Olomouc Czech Repub. 154:203–210. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Johnson ES, Lanes SF, Wentworth CE III,
Satterfield MH, Abebe BL and Dicker LW: A metaregression analysis
of the dose-response effect of aspirin on stroke. Arch Intern Med.
159:1248–1253. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Furie KL, Kasner SE, Adams RJ, et al:
Guidelines for the prevention of stroke in patients with stroke or
transient ischemic attack: a guideline for healthcare professionals
from the american heart association/american stroke association.
Stroke. 42:227–276. 2011. View Article : Google Scholar
|
|
13.
|
Antithrombotic Trialists’ Collaboration:
Collaborative meta-analysis of randomised trials of antiplatelet
therapy for prevention of death, myocardial infarction, and stroke
in high risk patients. BMJ. 324:71–86. 2002. View Article : Google Scholar
|
|
14.
|
CAPRIE Steering Committee: A randomised,
blinded trial of clopidogrel versus aspirin in patients at risk of
ischaemic events (CAPRIE). Lancet. 348:1329–1339. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
He J, Whelton PK, Vu B and Klag MJ:
Aspirin and risk of hemorrhagic stroke: a meta-analysis of
randomized controlled trials. JAMA. 280:1930–1935. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Topcuoglu MA, Arsava EM and Ay H:
Antiplatelet resistance in stroke. Expert Rev Neurother.
11:251–263. 2011. View Article : Google Scholar
|
|
17.
|
Lee JH, Cha JK, Lee SJ, Ha SW and Kwon SU:
Addition of cilostazol reduces biological aspirin resistance in
aspirin users with ischaemic stroke: a double-blind randomized
clinical trial. Eur J Neurol. 17:434–442. 2011.
|
|
18.
|
Maruyama H, Takeda H, Dembo T, et al:
Clopidogrel resistance and the effect of combination cilostazol in
patients with ischemic stroke or carotid artery stenting using the
VerifyNow P2Y12 Assay. Intern Med. 50:695–698. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Al-Qudah ZA, Hassan AE and Qureshi AI:
Cilostazol in patients with ischemic stroke. Expert Opin
Pharmacother. 12:1305–1315. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Huang Y, Cheng Y, Wu J, et al: Cilostazol
as an alternative to aspirin after ischaemic stroke: a randomised,
double-blind, pilot study. Lancet Neurol. 7:494–499. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Shinohara Y, Katayama Y, Uchiyama S, et
al: Cilostazol for prevention of secondary stroke (CSPS 2): an
aspirin-controlled, double-blind, randomised non-inferiority trial.
Lancet Neurol. 9:959–968. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Translational Research Informatics Center,
Hyogo, Japan: Cilostazol-aspirin therapy against recurrent stroke
with intracranial artery stenosis (CATHARSIS). 2009.http://www.strokecenter.org/trials/clinicalstudies/624uri.
Accessed 10 January 2012.
|
|
23.
|
Muhlestein JB: Effect of antiplatelet
therapy on inflammatory markers in atherothrombotic patients.
Thromb Haemost. 103:71–82. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Goto S: Cilostazol: potential mechanism of
action for anti-thrombotic effects accompanied by a low rate of
bleeding. Atheroscler Suppl. 6:3–11. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Omi H, Okayama N, Shimizu M, et al:
Cilostazol inhibits high glucose-mediated endothelial-neutrophil
adhesion by decreasing adhesion molecule expression via NO
production. Microvasc Res. 68:119–125. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Hong KW, Lee JH, Kima KY, Park SY and Lee
WS: Cilostazol: therapeutic potential against focal cerebral
ischemic damage. Curr Pharm Des. 12:565–573. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Honda F, Imai H, Ishikawa M, et al:
Cilostazol attenuates gray and white matter damage in a rodent
model of focal cerebral ischemia. Stroke. 37:223–228. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Lawes CM, Bennett DA, Feigin VL and
Rodgers A: Blood pressure and stroke: an overview of published
reviews. Stroke. 35:776–785. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Rashid P, Leonardi-Bee J and Bath P: Blood
pressure reduction and secondary prevention of stroke and other
vascular events: a systematic review. Stroke. 34:2741–2748. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Lindholm LH, Carlberg B and Samuelsson O:
Should beta blockers remain first choice in the treatment of
primary hypertension? A meta-analysis Lancet. 366:1545–1553.
2005.PubMed/NCBI
|
|
31.
|
Graham GD: Secondary stroke prevention:
from guidelines to clinical practice. J Natl Med Assoc. 1125–1137.
2008.PubMed/NCBI
|
|
32.
|
PROGRESS Collaborative Group: Randomised
trial of a perindopril-based blood-pressure-lowering regimen among
6,105 individuals with previous stroke or transient ischaemic
attack. Lancet. 358:1033–1041. 2001. View Article : Google Scholar
|
|
33.
|
Schrader J, Luders S, Kulschewski A, et
al: Morbidity and mortality after stroke, eprosartan compared with
nitrendipine for secondary prevention: principal results of a
prospective randomized controlled study (MOSES). Stroke.
36:1218–1226. 2005. View Article : Google Scholar
|
|
34.
|
Yusuf S, Teo KK, Pogue J, et al:
Telmisartan, ramipril, or both in patients at high risk for
vascular events. N Engl J Med. 358:1547–1559. 2008. View Article : Google Scholar
|
|
35.
|
Yusuf S, Diener HC, Sacco RL, et al:
Telmisartan to prevent recurrent stroke and cardiovascular events.
N Engl J Med. 359:1225–1237. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Weber R, Weimar C and Diener HC: Medical
prevention of stroke and stroke recurrence in patients with TIA and
minor stroke. Expert Opin Pharmacother. 10:1883–1894. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Collins R, Armitage J, Parish S, Sleight P
and Peto R; Heart Protection Study Collaborative Group: Effects of
cholesterol-lowering with simvastatin on stroke and other major
vascular events in 20536 people with cerebrovascular disease or
other high-risk conditions. Lancet. 363:757–767. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Amarenco P, Bogousslavsky J, Callahan A
III, et al: High-dose atorvastatin after stroke or transient
ischemic attack. N Engl J Med. 355:549–559. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Szapary L, Horvath B, Marton Z, et al:
Short-term effect of low-dose atorvastatin on haemorrheological
parameters, platelet aggregation and endothelial function in
patients with cerebrovascular disease and hyperlipidaemia. CNS
Drugs. 18:165–172. 2004. View Article : Google Scholar
|
|
40.
|
Ky B, Burke A, Tsimikas S, et al: The
influence of pravastatin and atorvastatin on markers of oxidative
stress in hypercholesterolemic humans. J Am Coll Cardiol.
51:1653–1662. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Araujo FA, Rocha MA, Mendes JB and Andrade
SP: Atorvastatin inhibits inflammatory angiogenesis in mice through
down regulation of VEGF, TNF-alpha and TGF-beta1. Biomed
Pharmacother. 64:29–34. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Selvin E, Coresh J, Shahar E, Zhang L,
Steffes M and Sharrett AR: Glycaemia (haemoglobin A1c) and incident
ischaemic stroke: the Atherosclerosis Risk in Communities (ARIC)
Study. Lancet Neur. 4:821–826. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Wilcox R, Bousser MG, Betteridge DJ, et
al: Effects of pioglitazone in patients with type 2 diabetes with
or without previous stroke: results from PROactive (PROspective
pioglitAzone Clinical Trial In macroVascular Events 04). Stroke.
38:865–873. 2007. View Article : Google Scholar
|
|
44.
|
Mori Y, Itoh Y, Obata T and Tajima N:
Effects of pioglitazone vs. glibenclamide on postprandial increases
in glucose and triglyceride levels and on oxidative stress in
Japanese patients with type 2 diabetes. Endocrine. 29:143–148.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Fujitaka K, Otani H, Jo F, et al:
Comparison of metabolic profile and adiponectin level with
pioglitazone versus voglibose in patients with type-2 diabetes
mellitus associated with metabolic syndrome. Endocrine. 58:425–432.
2011. View Article : Google Scholar
|
|
46.
|
Petrica L, Vlad A, Petrica M, et al:
Pioglitazone delays proximal tubule dysfunction and improves
cerebral vessels endothelial dysfunction in normoalbuminuric
patients with type 2 diabetes mellitus. Diabetes Res Clin Pract.
94:22–42. 2011. View Article : Google Scholar
|
